Project Grant R01CA293071
Award Date
6/1/25
Completion Date
5/31/30
Dollars Obligated
$356K
Federal Agency
National Cancer Institute
Federal Grant Program
93.396
Assistance Type
Project Grant
Place of Performance
Missouri, USA
Similar Awards
The National Cancer Institute (NCI) awarded a $696,569 Project Grant (CFDA 93.395 - Cancer Treatment Research) to New York University School of Medicine to conduct research aimed at developing novel therapies for lung cancer. The project, titled "Targeting LCN2, a Novel Therapy for Lung Cancer," will characterize the role of the immunosuppressive molecule lipocalin 2 (LCN2) in the tumor microenvironment and develop therapeutic antibodies that interfere with LCN2 function. The goal is...
This Project Grant award of $158,365 from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports research to understand the impact of NRF2 activation on lung squamous cell carcinoma (LUSC) initiation and progression. The University of North Carolina at Chapel Hill is the prime awardee and will develop a novel genetically-engineered mouse model to assess how activated NRF2 affects LUSC incidence, tumor characteristics, and the tumor microenvironment. The research aims to...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports research to develop effective therapeutic strategies for non-small cell lung cancers with SMARCA4 gene deficiencies. The $557,418 grant, awarded to Columbia University's Health Sciences Division, aims to evaluate the impact of selectively degrading the SMARCA2 protein as a treatment approach for this aggressive lung cancer subtype. The research leverages genetically engineered mouse...
The federal Project Grant award R01CA296978, in the amount of $703,410, was granted by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to New York University School of Medicine. The funding will support a comprehensive research program aimed at investigating the molecular mechanisms underlying the adeno-to-squamous transition (AST) in non-small cell lung cancer, which can lead to resistance to KRAS inhibitor treatments. The key products and services to be delivered...
The National Cancer Institute (NCI), under the Cancer Biology Research program (CFDA 93.396), awarded a $415,259 Project Grant to the Rector & Visitors of the University of Virginia (UVA) to study the role and mechanism of noncoding RNAs in primary and relapsed acute myeloid leukemia (AML). The award, effective from August 1, 2024 to July 31, 2026, aims to understand how noncoding RNAs, specifically a PU.1 enhancer RNA, can modulate the RUNX1-ETO/PU.1 axis and serve as important regulators...
This $230,010 Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) supports research to unravel the drivers of metastasis in small cell lung cancer (SCLC). The awardee, the University of Chicago, will leverage human pluripotent stem cell-derived pulmonary neuroendocrine cells to model critical stages of SCLC, from tumor initiation to metastatic spread. By examining cell behavior in primary tumors and metastatic sites using advanced...
The National Cancer Institute awarded a $645,323 Project Grant under the Cancer Biology Research (CFDA 93.396) program to The Washington University in St. Louis. The 5-year grant, running from February 1, 2025 to January 31, 2030, supports research into understanding the mechanisms by which acid signaling in bone metastases of breast cancer promotes immune suppression and tumor progression. The research aims to delineate how disruption of acid-induced G protein signaling in tumor cells and...
The National Cancer Institute (NCI) awarded a $730,400 Project Grant under the Cancer Biology Research program (CFDA 93.396) to the Sloan-Kettering Institute for Cancer Research. The five-year grant, running from December 1, 2024 to November 30, 2029, will support research to determine how specific configurations of the tricarboxylic acid (TCA) cycle metabolic pathway contribute to the development and maintenance of treatment-resistant lung adenocarcinoma (LUAD) cell states. The research aims to...
This federal Project Grant award, with ID R01CA289009, was provided by the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research program (CFDA 93.393). The grant supports research to elucidate the mechanistic roles of lineage factors in distinct lineage subtypes of small cell lung cancer (SCLC), a particularly aggressive form of lung cancer. The key objectives are to determine how cell-of-origin and the transcription factor NKX2-1 impact the evolution and maintenance...
This federal Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $649,679.00 to The Institute For Cancer Research to conduct research on targeting the DHX9 protein to trigger viral mimicry and enhance immunotherapy responsiveness in small cell lung cancer (SCLC). The key objectives are to: 1) Determine the role of DHX9 in inducing double-stranded RNAs and RNA-DNA hybrids that can activate antiviral signaling and compromise genome stability in...